Use of remdesivir in children with COVID-19 infection: a quick narrative review

SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in antivirals in children. We performed a quick narra...

Descripción completa

Detalles Bibliográficos
Autores principales: La Tessa, Andrea, Motisi, Marco Antonio, Marseglia, Gian Luigi, Cardinale, Fabio, Licari, Amelia, Manti, Sara, Tosca, Mariangela, Del Giudice, Michele Miraglia, De Filippo, Maria, Galli, Luisa, Chiappini, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431884/
https://www.ncbi.nlm.nih.gov/pubmed/34842595
http://dx.doi.org/10.23750/abm.v92iS7.12396
Descripción
Sumario:SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in antivirals in children. We performed a quick narrative review of the available literature data regarding the usage of remdesivir in children and neonates. In children, remdesivir showed good safety profile, however bradicardia events have been reported in children. Remdesivir is currently recommended by several guidelines in some subgroups of children with severe COVID-19, and should also be considered in critically ill patients, always in the context of the overall clinical picture and drug availability. (www.actabiomedica.it)

Ejemplares similares